▶ 調査レポート

セルベースアッセイの世界市場:製品別(細胞株、試薬・キット、その他の消耗品)、用途別(自動処理、フローサイトメトリー、ラベルフリー検出、ハイスループットスクリーニング、その他)、エンドユーザー別、地域別分析

• 英文タイトル:Global Cell-Based Assay Market - Segmented by Product, Technology, Application, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。セルベースアッセイの世界市場:製品別(細胞株、試薬・キット、その他の消耗品)、用途別(自動処理、フローサイトメトリー、ラベルフリー検出、ハイスループットスクリーニング、その他)、エンドユーザー別、地域別分析 / Global Cell-Based Assay Market - Segmented by Product, Technology, Application, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08113資料のイメージです。• レポートコード:B-MOR-08113
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥629,000 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥666,000 (USD4,500)▷ お問い合わせ
  Corporate User¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、セルベースアッセイの世界市場について調べ、セルベースアッセイの世界規模、市場動向、市場環境、製品別(細胞株、試薬・キット、その他の消耗品)分析、用途別(自動処理、フローサイトメトリー、ラベルフリー検出、ハイスループットスクリーニング、その他)分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・セルベースアッセイの世界市場インサイト
・セルベースアッセイの世界市場環境
・セルベースアッセイの世界市場動向
・セルベースアッセイの世界市場規模
・セルベースアッセイの世界市場規模:製品別(細胞株、試薬・キット、その他の消耗品)
・セルベースアッセイの世界市場規模:用途別(自動処理、フローサイトメトリー、ラベルフリー検出、ハイスループットスクリーニング、その他)
・セルベースアッセイの世界市場規模:エンドユーザー別
・セルベースアッセイの世界市場:地域別市場規模・分析
・セルベースアッセイの北米市場規模・予測
・セルベースアッセイのアメリカ市場規模・予測
・セルベースアッセイのヨーロッパ市場規模・予測
・セルベースアッセイのアジア市場規模・予測
・セルベースアッセイの日本市場規模・予測
・セルベースアッセイの中国市場規模・予測
・セルベースアッセイのインド市場規模・予測
・セルベースアッセイの韓国市場規模・予測
・関連企業情報・競争状況

The global cell-based assay market is expected to register a CAGR of 8.2% during the forecast period of 2018–2023. Cell-based assays are versatile research lab tool in healthcare, designed to target specific cells using antibodies or other moieties, to determine the functionality and efficacy of drugs. The higher expenditure on R&D, favorable government initiatives, and more technological advancements help North America to dominate this market.

Rising Chronic Diseases and Lifestyle Disorders

The rising prevalence of chronic diseases and lifestyle disorders, such as cancer, arthritis, cardiovascular, diabetes, and epilepsy, is one of the primary factors for the growth of this market. The cell-based assays for nervous system and chronic pain drug discovery provide new opportunities in the search for novel medicines for neurodegenerative diseases and pain. Cell-based assays are highly useful in screening mutagenesis in case of various types of cancers, such as chronic myeloid leukemia. According to the Center for Disease Control and Prevention, seven of the top 10 diseases in 2014 were chronic diseases. Thus, the rise in chronic diseases provides rising demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market.
Other factors playing a vital role for the growth of this market include increasing investments in R&D for drug discovery, technological advancements in cell-based methodologies, and rising adoption of high-throughput screening methods, particularly in toxicological studies.

High Maintenance and Operational Costs

One of the major factors restraining the cell-based assays market is the high maintenance of instruments and their operational costs. With the involvement of significant cost in operations, the market becomes less attractive in large-scale applications. For example, high cost associated with the CellKey system and RT-CES. With that, there is an increased cost for coated plates, which are not readily affordable. This forces several companies and research labs to find cost-effective alternatives, such as pre-treating of plates with collagen, thereby, impeding the growth of the market.
Along with this, other factors such as lack of skilled professionals and stringent regulatory pathways linked to instruments, reagents, and kits hamper the growth of this market.

United States to Hold the Largest Market Share

The United States is expected to have the largest market share in the forecast period. The dominance is primarily attributed to the rising availability of funds for research and extensive drug discovery activities in the country from multinational firms in collaborations with domestic companies and research institutes. The Asia-Pacific region also posses a potential market for the growth of cell-based assays due to a large patient pool, rising economies, and rising assays applications, with China and India being profitable markets.

Key Developments in the Market

• February 2018: Imec, one of the leaders in nanoelectronics and digital technologies, designed and fabricated a 16,384-electrode, 1,024-channel micro-electrode array for high-throughput multi-modal cell interfacing.
• January 2018: Agilent Technologies expanded its cell analysis portfolio by the acquisition of Luxcel Biosciences, involved in the development of real-time fluorescence plate-reader based on in-vitro cell assay kits.

Major players: BECTON, DICKINSON AND COMPANY, BIO-RAD LABORATORIES, INC., CORNING, INC., DANAHER CORPORATION, DISCOVERX CORPORATION, F. HOFFMANN-LA ROCHE LTD, MERCK KGAA, PERKIN ELMER, INC., PROMEGA CORPORATION, AND THERMO FISHER SCIENTIFIC, INC., amongst others.

Reasons to Purchase the Report

• A look at the current and future of the global cell-based assays market in the developed and emerging regions.
• Analyzing various perspectives of the market with the help of Porter’s Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
6.1.2 Increasing Investments in Research and Development for Drug Discovery
6.1.3 Rise in Technological Advancements in Cell-based Methodologies
6.1.4 Rising Adoption of High-Throughput Screening Methods
6.2 Restraints
6.2.1 High Maintenance and Operational Costs
6.2.2 Lack of Skilled Personnels to Operate these Technologies
6.2.3 Stringent Regulatory Pathways
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Product
7.1.1 Cell Lines
7.1.1.1 Primary Cell Lines
7.1.1.2 Stem Cell Lines
7.1.1.3 Others
7.1.2 Reagents and Kits
7.1.3 Mircoplates
7.1.4 Other Consumables
7.2 By Technology
7.2.1 Automated Handling
7.2.2 Flow Cytometry
7.2.3 Label-Free Detection
7.2.4 High-Throughput Screening
7.2.5 Others
7.3 By Application
7.3.1 Drug Discovery
7.3.2 ADME Studies
7.3.3 Other Applications
7.4 By End User
7.4.1 Academia
7.4.2 Pharmaceutical and Biotechnology Companies
7.4.3 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.1.4 Rest of North America
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 United Kingdom
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of the Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Becton, Dickinson and Company
9.2 Bio-Rad Laboratories, Inc.
9.3 Corning, Inc.
9.4 Danaher Corporation
9.5 DiscoverX Corporation
9.6 F. Hoffmann-La Roche Ltd
9.7 Merck KGaA
9.8 Perkin Elmer, Inc.
9.9 Promega Corporation
9.10 Thermo Fisher Scientific, Inc.
9.11 List not Exhaustive
10. Future of the Market